Related Experiment Video
Updated: May 15, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
New anticoagulants in atrial fibrillation: an update for clinicians
Abstract:
Anticoagulation is vital for stroke and systemic embolism prevention in patients with atrial fibrillation. Current therapy with the vitamin K inhibitor warfarin has many inherent limitations in clinical practice. With the potential of broadening anticoagulation therapy to a larger population, new classes of anticoagulants have recently emerged with the potential for improved efficacy, safety and convenience. Direct thrombin inhibitor and Factor Xa inhibitor classes are showing promise for both patients and clinicians.
Insights
New anticoagulants offer improved efficacy, safety, and convenience for preventing stroke and embolism in atrial fibrillation patients. Direct thrombin and Factor Xa inhibitors show promise beyond traditional warfarin therapy.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Anticoagulation is crucial for preventing stroke and systemic embolism in atrial fibrillation (AF) patients.
- Vitamin K antagonists like warfarin have limitations in clinical practice.
- There is a need for anticoagulants with improved efficacy, safety, and convenience.
Purpose of the Study:
- To review emerging anticoagulant classes for AF patients.
- To highlight the potential benefits of new anticoagulants over warfarin.
Main Methods:
- Review of current literature on anticoagulation therapies for AF.
- Analysis of emerging direct thrombin inhibitors and Factor Xa inhibitors.
Main Results:
- New anticoagulant classes demonstrate potential for enhanced efficacy and safety.
- Direct thrombin and Factor Xa inhibitors offer improved convenience compared to warfarin.
Conclusions:
- Emerging anticoagulants represent a significant advancement in AF management.
- Direct thrombin and Factor Xa inhibitors are promising alternatives for stroke prevention in AF.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...

